BUSINESS

Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura

September 4, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Kyowa Kirin said on September 3 that the biosimilar version of the cancer agent Rituxan (rituximab) from its strategic collaborator Sandoz has received approval in Japan for additional indications of chronic idiopathic thrombocytopenic purpura and as premedication of ibritumomab tiuxetan.…

To read the full story

Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020

BUSINESS

Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
Alfresa Invests in Digital Health Startup eMind
June 24, 2026
Daito Scores China Approval for Myonal Generic
June 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…